Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Surgical Oncology

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-016-5599-zPMID 27696172
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer

  2015cited by this paper
• MET Gene Copy Number Predicts Worse Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC); A Systematic Review and Meta-Analysis

  2014cited by this paper
• EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer

  2014cited by this paper
• c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer.

  2014cited by this paper
• Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

  2014cited by this paper
• Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures

  2014cited by this paper
• Diagnostic Value of Mutation-Specific Antibodies for Immunohistochemical Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

  2014cited by this paper
• MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

  2014cited by this paper
• Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells

  2014cited by this paper
• c-MET Inhibitors in the Treatment of Lung Cancer

  2014cited by this paper
• Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.

  2013cited by this paper
• EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma

  2013cited by this paper
• Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy

  2013cited by this paper
• Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

  2013cited by this paper
• High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.

  2012cited by this paper
• Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

  2011cited by this paper
• HGF-independent Potentiation of EGFR Action by c-Met

  2011cited by this paper
• A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

  2011cited by this paper
• Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

  2011cited by this paper
• Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

  2010cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

  2009cited by this paper
• Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

  2009cited by this paper
• Molecular predictive and prognostic markers in non-small-cell lung cancer.

  2009cited by this paper
• EGFR testing in lung cancer is ready for prime time.

  2009cited by this paper
• Targeting the c-MET signaling pathway for cancer therapy.

  2008cited by this paper
• Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

  2008cited by this paper
• A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras

  2008cited by this paper
• Signaling networks assembled by oncogenic EGFR and c-Met

  2008cited by this paper
• Targeting the c-MET signaling pathway for cancer therapy

  2008cited by this paper
• Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

  2008cited by this paper
• Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

  2007cited by this paper
• Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer

  2007cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables.

  2006cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.

  2000cited by this paper
• Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.

  1996cited by this paper

• Co-expression of a truncated TGFβ receptor II in c-Met CAR T cells enhances antitumor activity against lung adenocarcinoma

  2025cites this paper
• Similar trend in benefit of adjuvant platinum in lung cancer patients irrespective of epidermal growth factor receptor mutation status.

  2025cites this paper
• A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

  2023cites this paper
• KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block

  2021cites this paper
• Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer

  2020cites this paper
• The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis

  2019cites this paper
• Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis

  2019cites this paper
• c-MET as a biomarker in patients with surgically resected non-small cell lung cancer.

  2019cites this paper
• Correlation analysis of mesenchymal–epithelial transition factor protein and human epidermal growth receptor 2 protein expression in 1479 cases of lung adenocarcinoma in China

  2018cites this paper
• EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

  2018cites this paper